美國(guó)VaxInnate www.vaxinnate.com
VaxInnate公司是一家私人持有的生物技術(shù)公司，開發(fā)新穎，專有疫苗為大流行病和季節(jié)性流感。該公司的突破疫苗是基于其Toll樣受體（ TLR為）的技術(shù)平臺(tái)，大大提高了疫苗的免疫原性和有效性。利用TLR為技術(shù)，疫苗可產(chǎn)生的簡(jiǎn)單，低成本，高可擴(kuò)展性重組DNA技術(shù)，避免許多挑戰(zhàn)和隱患的雞蛋或細(xì)胞培養(yǎng)流感疫苗的生產(chǎn)。 VaxInnate的技術(shù)有可能顯著提高成本效益，制造能力和效力的流感疫苗-面臨的關(guān)鍵問題的臨床和公共健康的社區(qū)。 

美國(guó)生物制藥公司VaxInnate總裁艾倫·肖在接受新華社記者采訪時(shí)表示，針對(duì)這種新型病毒(豬流感病毒)的疫苗樣品有望在4周內(nèi)研制成功。
VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy. Using the TLR technology, vaccines can be produced by simple, low-cost, highly-scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture influenza vaccine production. VaxInnate's technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines - key issues facing the clinical and public health communities.
 
VaxInnate has a BSL2+ laboratory operational within the Cranbury site, and also has access to BSL-2 vivarium space through a collaborative research agreement with Yale University . VaxInnate also has a collaborative arrangement with an academic institution for access to high level biocontainment facilities (BSL-3 and -4). Since avian influenza requires BSL-3 or -4 facilities, depending on the strain in question, this access enables the VaxInnate to conduct live virus challenges in animal models.